Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-HIPEC Cytoreduction
2016-000823-24Phase 2Completed
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Jun 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitomycin c, cisplatin and doxorubicin in peritoneal carcinomatosis (PC), gastric cancer (GC), colon cancer and 4 more, sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoint: Feasibility of optimal cytoreduction. Started Jun 2021; status: completed.
02
Drugs
mitomycin ccisplatindoxorubicin
03
Conditions
peritoneal carcinomatosis (PC)gastric cancer (GC)colon cancerovarian cancerpseudomyxoma peritonei (PMP)
Beyond the preview
Go deeper on 2016-000823-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000823-24.